CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 2024 Healthcare Virtual Summit presented by Maxim Group John Climaco, CEO of CNS Pharmaceuticals, will engage in a fireside chat on Wednesday, October 16th at 4:00 PM ET.
The summit will feature a series of presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology. Maxim Senior Analysts will host these sessions and conduct several topical industry panels.
Interested participants can attend the virtual event by signing up for an M-Vest membership. Further updates about the summit will be provided to registered attendees.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), una società biopharmaceutica focalizzata nello sviluppo di nuovi trattamenti per i tumori del cervello e del sistema nervoso centrale, ha annunciato la sua partecipazione al 2024 Healthcare Virtual Summit presentato da Maxim Group. John Climaco, CEO di CNS Pharmaceuticals, prenderà parte a una discussione al fuoco mercoledì 16 ottobre alle 16:00 ET.
Il summit presenterà una serie di interventi e discussioni interattive con CEO e figure chiave della gestione provenienti da vari settori della salute, tra cui biotecnologie, diagnostica, dispositivi medici e tecnologie dell'informazione sanitaria. Gli analisti senior di Maxim ospiteranno queste sessioni e condurranno diversi panel tematici sull'industria.
I partecipanti interessati possono partecipare all'evento virtuale registrandosi per un M-Vest membership. Ulteriori aggiornamenti sul summit saranno forniti ai partecipanti registrati.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), una compañía biofarmacéutica enfocada en desarrollar nuevos tratamientos para cánceres del cerebro y del sistema nervioso central, ha anunciado su participación en el 2024 Healthcare Virtual Summit presentado por Maxim Group. John Climaco, CEO de CNS Pharmaceuticals, participará en una charla junto a la chimenea el miércoles 16 de octubre a las 4:00 PM ET.
La cumbre contará con una serie de presentaciones y discusiones interactivas con CEOs y alta dirección de diversos sectores de la salud, incluyendo biotecnología, diagnóstico, dispositivos médicos y tecnología de información en salud. Los analistas senior de Maxim serán los encargados de moderar estas sesiones y llevar a cabo varios paneles temáticos de la industria.
Los participantes interesados podrán asistir al evento virtual registrándose para una M-Vest membership. Se proporcionarán más actualizaciones sobre la cumbre a los asistentes registrados.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), 뇌 및 중앙 신경계 암을 위한 새로운 치료법 개발에 주력하는 생명공학 회사가 2024 Healthcare Virtual Summit에 참여한다고 발표했습니다. John Climaco CNS Pharmaceuticals의 CEO가 10월 16일 수요일 오후 4시(ET)에 화로 앞 대화에 참여합니다.
이번 정상 회담에서는 생명공학, 진단, 의료 기기, 헬스케어 정보 기술 등 다양한 헬스케어 분야의 CEO 및 주요 경영진과의 발표 및 대화가 진행될 예정입니다. Maxim의 선임 애널리스트들이 이 세션을 주최하고 여러 산업 주제 패널을 진행할 예정입니다.
관심 있는 참여자는 M-Vest membership에 가입하여 가상 이벤트에 참석할 수 있습니다. 정상 회담에 대한 추가 업데이트는 등록된 참석자에게 제공됩니다.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), une société biopharmaceutique spécialisée dans le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation au 2024 Healthcare Virtual Summit présenté par Maxim Group. John Climaco, PDG de CNS Pharmaceuticals, participera à une discussion au coin du feu le mercredi 16 octobre à 16h00 ET.
Le sommet présentera une série de présentations et de discussions interactives avec des PDG et des responsables clés de divers secteurs de la santé, y compris la biotechnologie, le diagnostic, les dispositifs médicaux et la technologie de l'information en santé. Des analystes seniors de Maxim animeront ces sessions et dirigeront plusieurs panels thématiques sur l'industrie.
Les participants intéressés peuvent assister à l'événement virtuel en s'inscrivant pour un M-Vest membership. Des mises à jour supplémentaires concernant le sommet seront fournies aux participants enregistrés.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Behandlungen für Krebs im Gehirn und im zentralen Nervensystem konzentriert, hat seine Teilnahme am 2024 Healthcare Virtual Summit bekannt gegeben, der von Maxim Group präsentiert wird. John Climaco, CEO von CNS Pharmaceuticals, wird am Mittwoch, den 16. Oktober um 16:00 Uhr ET an einem Feuerplatzgespräch teilnehmen.
Die Cembretagung wird eine Reihe von Präsentationen und interaktiven Diskussionen mit CEOs und führenden Führungskräften aus verschiedenen Gesundheitssektoren umfassen, darunter Biotechnologie, Diagnostik, medizinische Geräte und Gesundheitsinformations-technologie. Senior Analysten von Maxim werden diese Sitzungen moderieren und mehrere thematische Branchenpanels durchführen.
Interessierte Teilnehmer können an der virtuellen Veranstaltung teilnehmen, indem sie sich für eine M-Vest membership anmelden. Weitere Informationen zum Summit werden den registrierten Teilnehmern zur Verfügung gestellt.
- None.
- None.
Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET
HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 16,2024 at 4:00 PM ET.
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. Additionally, Maxim plans to host several topical industry panels that promise to be timely and engaging. To attend, just sign up to become an M-Vest member and stay tuned for more updates.
Click Here to Reserve Your Seat.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is CNS Pharmaceuticals (CNSP) participating in the 2024 Healthcare Virtual Summit?
Who will represent CNS Pharmaceuticals (CNSP) at the 2024 Healthcare Virtual Summit?
What is the focus of CNS Pharmaceuticals (CNSP)?
How can investors attend the 2024 Healthcare Virtual Summit featuring CNS Pharmaceuticals (CNSP)?
